CA2277273C - Antagonistes d'integrine - Google Patents

Antagonistes d'integrine Download PDF

Info

Publication number
CA2277273C
CA2277273C CA002277273A CA2277273A CA2277273C CA 2277273 C CA2277273 C CA 2277273C CA 002277273 A CA002277273 A CA 002277273A CA 2277273 A CA2277273 A CA 2277273A CA 2277273 C CA2277273 C CA 2277273C
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
compound
alkyl
inhibition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002277273A
Other languages
English (en)
Other versions
CA2277273A1 (fr
Inventor
Mark E. Duggan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9702788.2A external-priority patent/GB9702788D0/en
Priority claimed from GBGB9725996.4A external-priority patent/GB9725996D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of CA2277273A1 publication Critical patent/CA2277273A1/fr
Application granted granted Critical
Publication of CA2277273C publication Critical patent/CA2277273C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne certains nouveaux composés et leurs derivés, leur synthèse et leur utilisation comme antagonistes de récepteur vitronectine. Les composés antagonistes de récepteur de vitronectine décrits sont des antagonistes alpha v beta 3, des antagonistes alpha v beta 5 ou des antagonistes doubles alpha v beta 3/ alpha v beta 5, utiles pour inhiber la résorption osseuse, traiter et prévenir l'ostéoporose et inhiber la resténose, la rétinopathie diabétique, la dégénérescence maculaire, l'angiogénèse, l'athérosclérose, l'inflammation, les maladies virales et la croissance tumorale.
CA002277273A 1997-01-17 1998-01-13 Antagonistes d'integrine Expired - Fee Related CA2277273C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US3561497P 1997-01-17 1997-01-17
US60/035,614 1997-01-17
GBGB9702788.2A GB9702788D0 (en) 1997-02-11 1997-02-11 Alpha v beta 3 antagonists
GB9702788.2 1997-02-11
US6259497P 1997-10-20 1997-10-20
US60/062,594 1997-10-20
GBGB9725996.4A GB9725996D0 (en) 1997-12-09 1997-12-09 Intergrin antagonists
GB9725996.4 1997-12-09
PCT/US1998/000617 WO1998031359A1 (fr) 1997-01-17 1998-01-13 Antagonistes d'integrine

Publications (2)

Publication Number Publication Date
CA2277273A1 CA2277273A1 (fr) 1998-07-23
CA2277273C true CA2277273C (fr) 2008-03-25

Family

ID=27451601

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002277273A Expired - Fee Related CA2277273C (fr) 1997-01-17 1998-01-13 Antagonistes d'integrine

Country Status (5)

Country Link
EP (1) EP1007026A4 (fr)
JP (1) JP2001509176A (fr)
AU (1) AU729869B2 (fr)
CA (1) CA2277273C (fr)
WO (1) WO1998031359A1 (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629816A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6211191B1 (en) 1997-12-17 2001-04-03 Merck & Co., Inc. Integrin receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
US6066648A (en) 1997-12-17 2000-05-23 Merck & Co., Inc. Integrin receptor antagonists
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
US6313119B1 (en) 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6984400B2 (en) 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
WO2000006169A1 (fr) * 1998-07-29 2000-02-10 Merck & Co., Inc. Antagonistes des recepteurs de l'integrine
DE19842415A1 (de) * 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
RU2219172C2 (ru) 1999-04-06 2003-12-20 Санкио Компани, Лимитед α-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ
GB9908355D0 (en) * 1999-04-12 1999-06-09 Rhone Poulenc Rorer Ltd Chemical compounds
GB9910394D0 (en) * 1999-05-05 1999-07-07 Rhone Poulenc Rorer Ltd Chemical compounds
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
SK17442001A3 (sk) 1999-06-02 2002-03-05 Merck & Co., Inc. Deriváty kyseliny nonánovej, farmaceutický prostriedok s ich obsahom a ich použitie
EP1187825A1 (fr) 1999-06-07 2002-03-20 Shire Biochem Inc. Inhibiteurs d'integrine thiophene
EP1065207A1 (fr) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Dérivées de la naphthyridine, procédés pour leur preparation, leur utilisation, et compositions pharmaceutique les contenant
EP1065208A1 (fr) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Dérivés substitués de la purine inhibiteurs de l'adhésion cellulaire
AU6360200A (en) * 1999-07-21 2001-02-13 American Home Products Corporation Bicyclic antagonists selective for the alphavbeta3 integrin
WO2001010844A1 (fr) 1999-08-05 2001-02-15 Meiji Seika Kaisha, Ltd. DERIVES D'ACIDE φ-AMINO-α-HYDROXYCARBOXYLIQUE POSSEDANT UN ANTAGONISME αvβ3 D'INTEGRINE
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
AU2001248553A1 (en) 2000-04-17 2001-10-30 Celltech R And D Limited Enamine derivatives as cell adhesion molecules
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
AU2001269821A1 (en) 2000-06-15 2001-12-24 Barbara Chen Cycloalkyl alkanoic acids as integrin receptor antagonists
AU2001268490A1 (en) 2000-06-15 2001-12-24 Pharmacia Corporation Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
US6638950B2 (en) 2000-06-21 2003-10-28 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
AU2001267753A1 (en) 2000-07-07 2002-01-21 Celltech R And D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
JP2004505110A (ja) 2000-08-02 2004-02-19 セルテック　アール　アンド　ディ　リミテッド ３位置換イソキノリン−１−イル誘導体
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
JP4660067B2 (ja) 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血管新生剤とＴＮＦαとを用いる組合せ療法
JP2005516054A (ja) 2002-01-29 2005-06-02 ワイス コネキシンヘミチャンネルを調節する組成物及びその方法
US7365209B2 (en) * 2003-02-11 2008-04-29 Pharmacopeia, Inc. Nitrogen heterocycle biaryls for osteoporosis and other diseases
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
BRPI0414604A (pt) * 2003-09-23 2006-11-07 Novartis Ag combinações de um inibiddor do receptor de vegf com outros agentes terapêuticos
WO2007084670A2 (fr) 2006-01-18 2007-07-26 Merck Patent Gmbh Traitement specifique utilisant des ligands de l’integrine destine a traiter un cancer
PT2007752E (pt) 2006-03-31 2010-10-18 Janssen Pharmaceutica Nv Benzoimidazol-2-il pirimidinas e pirazinas como moduladores do receptor de histamina h4
JP2009532367A (ja) 2006-03-31 2009-09-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のモジュレーターとしてのベンゾイミダゾール−２−イルピリジン
DK2101805T3 (da) 2007-01-18 2013-01-21 Merck Patent Gmbh Integrinligander til anvendelse i behandling af cancer
US8084466B2 (en) 2007-12-18 2011-12-27 Janssen Pharmaceutica Nv Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
US20120130146A1 (en) 2009-05-25 2012-05-24 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
MY180726A (en) 2013-03-06 2020-12-08 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
JP6215335B2 (ja) 2013-09-24 2017-10-18 富士フイルム株式会社 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体
BR112016027778A2 (pt) 2014-05-30 2017-08-15 Pfizer Usos de derivados de carbonitrila, sua combinação e sua composição farmacêutica
CN109996541A (zh) 2016-09-07 2019-07-09 普利安特治疗公司 N-酰基氨基酸化合物及其使用方法
WO2023275715A1 (fr) 2021-06-30 2023-01-05 Pfizer Inc. Métabolites de modulateurs sélectifs du récepteur des androgènes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0673247A4 (fr) * 1992-12-01 1996-05-01 Merck & Co Inc Antagonistes des recepteurs du fibrinogene.
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
WO1995032710A1 (fr) * 1994-05-27 1995-12-07 Merck & Co., Inc. Composes inhibiteurs de la resorption osseuse induite par osteoclaste

Also Published As

Publication number Publication date
JP2001509176A (ja) 2001-07-10
AU729869B2 (en) 2001-02-15
CA2277273A1 (fr) 1998-07-23
WO1998031359A1 (fr) 1998-07-23
AU6023198A (en) 1998-08-07
EP1007026A4 (fr) 2002-08-07
EP1007026A1 (fr) 2000-06-14

Similar Documents

Publication Publication Date Title
CA2277273C (fr) Antagonistes d'integrine
AU722360B2 (en) Integrin antagonists
US6017925A (en) Integrin antagonists
AU717283B2 (en) Integrin antagonists
AU748621B2 (en) Integrin receptor antagonists
AU747784B2 (en) Integrin receptor antagonists
US5919792A (en) Integrin antagonists
AU720758B2 (en) Alphavbeta3 antagonists
US6413955B1 (en) Integrin receptor antagonists
US5952341A (en) Integrin antagonists
AU747503B2 (en) Benzazepine derivatives as alpha-V integrin receptor antagonists
AU1912899A (en) Integrin receptor antagonists
EP1194151A1 (fr) Antagonistes des recepteurs de l'integrine
US5925655A (en) αv β3 antagonists
US6211184B1 (en) Integrin antagonists
US6294549B1 (en) Method for eliciting an αvβ5 or dual αvβ3/αvβ5 antagonizing effect
US6916810B2 (en) αν integrin receptor antagonists
CA2268916A1 (fr) Antagonistes de l'integrine
Duggan et al. α v β 3 antagonists

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed